Afatinib Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT02716311Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
NCT02183883Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
NCT03157089Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung